Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sutro Biopharma Inc (NQ: STRO )

2.650 -0.040 (-1.49%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sutro Biopharma Inc

< Previous 1 2 3 Next >
52 Weeks High And Low Article
On Friday, 106 companies reached new 52-week lows. Things to Consider About Today's 52-Week Lows: Air Products & Chemicals (NYSE:APD) is the largest company... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
On Friday, 209 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Meta Platforms (NASDAQ:FB) was the largest firm on a market cap... 
Via Benzinga
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
Stocks That Hit 52-Week Lows On Monday
During Monday's session, 291 companies made new 52-week lows. Also check out this: Insiders Buying These 4 Penny Stocks Noteable 52-Week Lows And Highs: SAP (... 
Via Benzinga
7 Triple-F-Rated Stocks That Have No Hope in Sight
The contrarian in a lot of people perks up during selloffs like the one we're in right now, but don't let these F-rated stocks tempt you. 
Via InvestorPlace
58 Biggest Movers From Yesterday
Gainers Eargo, Inc. (NASDAQ: EAR) shares climbed 59.7% to close at $7.28 on Thurs after the company announced the Department of Justice confirmed to it that the previously-... 
Via Benzinga
Sutro Biopharma Collapses; Why One Analyst Remains Bullish On Its Chances In Cancer
Sutro Biopharma could still find a place for itself in ovarian cancer treatment. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Eargo (NASDAQ:EAR) stock increased by 50.0% to $6.84 during Thursday's regular session. The current volume of 90.4 million shares is 5474.6% of Eargo's... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 615 stocks hit new 52-week lows. Noteable 52-Week Lows: Sea (NYSE:SE) is the largest company in terms of market cap to set a new 52-week low this... 
Via Benzinga
33 Stocks Moving In Thursday's Mid-Day Session
Gainers Eargo, Inc. (NASDAQ: EAR) shares jumped 50.8% to $6.88 after the company announced the Department of Justice confirmed to it that the previously-announced criminal probe... 
Via Benzinga
The Daily Biotech Pulse: Lilly Strikes Neurological R&D Collaboration, Valneva Confirms Vaccine Timelines, Biohaven Gains On Strong Migraine Drug Sales
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Illumina Announces Co-Development Partnership With SomaScan For Accelerating... 
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease Study Disappoints, Amneal Buys Neurology Assets
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Annexon Announces Mixed Phase 2 Data From Huntington Disease Trial Annexon,... 
Via Benzinga
The Week Ahead In Biotech (Jan. 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week
Biotech stocks came under selling pressure in the final week of 2021, although they carved out modest gains for the year. Here are the key catalysts that can sway biotech stocks in the unfolding week. 
Via Talk Markets
The Week Ahead In Biotech (Jan 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week
Biotech stocks came under selling pressure in the final week of 2021, although they carved out modest gains for the year. On the regulatory front, the Food And Drug Administration... 
Via Benzinga
Week In Review: Tasly Pharma Acquires Sutro ADC In $385 Million Deal
Tasly Pharma acquired Greater China rights to an antibody-drug conjugate from Sutro Biopharma in a deal worth up to $385 million. Sutro will receive an upfront payment of $40 million and be eligible... 
Via Talk Markets
Sutro Biopharma Earnings Perspective: Return On Capital Employed
Benzinga Pro data, Sutro Biopharma (NASDAQ:STRO) reported Q3 sales of $8.52 million. Earnings fell to a loss of $34.67 million, resulting in a 253.64% decrease from last quarter... 
Via Benzinga
Week In Review: Hansoh Signs $456 Million Deal For siRNA Products
Hansoh Pharma of Shanghai announced a $456 million agreement to develop siRNA products in Greater China from South Korea's OliX Pharma. Hansoh will make an upfront payment of $6.5 million and up to... 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2021
Upgrades According to Williams Capital, the prior rating for On Holding AG (NYSE: 
Via Benzinga
Merck, Sutro Biopharma Extends Cytokine Derivative Research Program
Merck & Co Inc (NYSE: MRK) has extended the research term by two years for the first cytokine derivative program under a 2018 agreement with Sutro... 
Via Benzinga
Sutro Biopharma Earnings Perspective: Return On Capital Employed
According to Benzinga Pro data, during Q2, Sutro Biopharma (NASDAQ:STRO) posted sales of $28.05 million. Earnings were up 48.42%, but Sutro Biopharma still reported an overall... 
Via Benzinga
Sutro Biopharma's Ovarian Cancer Candidate Fast Tracked In US
The FDA has granted Fast Track designation to Sutro Biopharma Inc's (NASDAQ: STRO) STRO-002 for ovarian cancer. The designation covers platinum-resistant... 
Via Benzinga
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For June 18, 2021
Upgrades According to JP Morgan, the prior rating for Orion Engineered Carbons SA (NYSE: 
Via Benzinga
Sutro Biopharma Receives Undisclosed Milestone Payment Under Bispecific ADC Collaboration with Merck
Sutro Biopharma Inc (NASDAQ: STRO) has received a milestone payment under its collaboration and license agreement with the healthcare division of Merck KGaA... 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.